Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00589914 · ClinicalTrials.gov registry record · Phase 3
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
A Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- Completed
- Registry status
- Phase 3
- Development phase
- 1,221
- Enrollment target
NCT00589914: Completed Phase 3 study, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
NCT00589914 is a Phase 3 study that has completed, run by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. The registered enrollment target is 1,221 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00589914, a Phase 3 study, has completed, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,221 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the effectiveness of paliperidone palmitate in patients with Schizophrenia.
Primary Outcome
The PANSS scale is used to assess the neuropsychiatric symptoms of schizophrenia. The 30-item PANSS scale provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items),and the general psychopathology subscale (16 items), each item rated on a scale of 1 (absent) to 7 (extreme).
Interventions
- DRUG Paliperidone palmitate
- DRUG RISPERDAL CONSTA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,221 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
What the finished NCT00589914 record still lists
NCT00589914 is an interventional study that assigns participants to a tested intervention. Its 1,221 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (58% higher).
The record links to 0 conditions, and to 2 interventions - of which Paliperidone palmitate is the first listed.
NCT00589914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00589914 about?
NCT00589914 is a clinical study titled "Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia". The purpose of this study is to demonstrate the effectiveness of paliperidone palmitate in patients with Schizophrenia.
What is the current status of trial NCT00589914?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,221 participants. The study started on 2007-03. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00589914?
The interventions under investigation include: Paliperidone palmitate (DRUG), RISPERDAL CONSTA (DRUG).
Who is sponsoring clinical trial NCT00589914?
This trial is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., which has 102 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00589914's enrollment target sits among peer trials
1,221 214th of 2000 higher than 1,787 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06921785 · 1,220 participants · Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
- NCT06143956 · 1,217 participants · Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- NCT05827016 · 1,216 participants · Phase 3
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
- NCT05946044 · 1,230 participants · NA
The Osteoarthritis Prevention Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia